About Ulteemit BioConsulting
Dr. Michiel “Mike” E. Ultee formed Ulteemit BioConsulting in October 2013 to offer expert consultation in the fields of process development and manufacture of protein therapeutics. With over 30 years experience in the development of biopharmaceuticals, from research through commercial manufacturing, Dr. Ultee offers both creative insight and a rich perspective into what it takes to turn a protein discovery into a therapeutic.
Recognized as an industry subject-matter expert on antibodies, fusion proteins and other recombinant proteins, Dr. Ultee is a frequent speaker at international conferences such Bioprocessing International, Biopharm Production Week, Bioproduction, and the Biotechnology Industry Organization. He serves on the Editorial Advisory Boards of Biopharm International and Bioprocess International, and is frequently interviewed by these publications and others. He was twice honored as the keynote speaker at the Downstream Technology Forum held in Bethesda, MD.
“The Road to the Biologic IND” is a special program created by Dr. Ultee for those in the research and discovery to understand better the steps and commitments required to successfully develop and manufacture an early-phase biopharmaceutical. It has now been presented in ten cities across the county, often to capacity crowds.
Dr. Ultee has published a wide variety of papers of all aspects of bioprocessing. These include an in-depth review of antibody purification techniques for the
Encyclopedia of Industrial Biotechnology, initially in 1999 and then for its second edition in 2010. Other papers have focused on the production and purification of challenging proteins, including fusion proteins and IgM antibodies. He has also published on radiolabeled antibodies for nuclear medicine applications, as well as a novel method for the production of antibody fragments. More recently has presented and published multiple times on single-use applications in bioprocessing.
As the scientific co-founder and CSO of Laureate Biopharma, where he worked for many years, Dr. Ultee succeeded in developing dozens of proteins into new
biopharmaceuticals for Laureate’s clients. Through these activities as well as his publications and presentations, he became well known, respected and widely connected in the industry. When Gallus Biopharmaceuticals acquired Laureate on October 1, 2013, Dr. Ultee agreed to become their CSO in a part-time position. This arrangement allows him to continue to work on new biopharmaceutical challenges for Gallus’ clients, while also permitting him time to consult for others. He looks forward to working with you in solving your bioprocessing challenges.
Recognized as an industry subject-matter expert on antibodies, fusion proteins and other recombinant proteins, Dr. Ultee is a frequent speaker at international conferences such Bioprocessing International, Biopharm Production Week, Bioproduction, and the Biotechnology Industry Organization. He serves on the Editorial Advisory Boards of Biopharm International and Bioprocess International, and is frequently interviewed by these publications and others. He was twice honored as the keynote speaker at the Downstream Technology Forum held in Bethesda, MD.
“The Road to the Biologic IND” is a special program created by Dr. Ultee for those in the research and discovery to understand better the steps and commitments required to successfully develop and manufacture an early-phase biopharmaceutical. It has now been presented in ten cities across the county, often to capacity crowds.
Dr. Ultee has published a wide variety of papers of all aspects of bioprocessing. These include an in-depth review of antibody purification techniques for the
Encyclopedia of Industrial Biotechnology, initially in 1999 and then for its second edition in 2010. Other papers have focused on the production and purification of challenging proteins, including fusion proteins and IgM antibodies. He has also published on radiolabeled antibodies for nuclear medicine applications, as well as a novel method for the production of antibody fragments. More recently has presented and published multiple times on single-use applications in bioprocessing.
As the scientific co-founder and CSO of Laureate Biopharma, where he worked for many years, Dr. Ultee succeeded in developing dozens of proteins into new
biopharmaceuticals for Laureate’s clients. Through these activities as well as his publications and presentations, he became well known, respected and widely connected in the industry. When Gallus Biopharmaceuticals acquired Laureate on October 1, 2013, Dr. Ultee agreed to become their CSO in a part-time position. This arrangement allows him to continue to work on new biopharmaceutical challenges for Gallus’ clients, while also permitting him time to consult for others. He looks forward to working with you in solving your bioprocessing challenges.